Betamethasone Scalp Suspension 0.064%;0.0005% + Taclonex® + Placebo topical suspension
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Scalp Psoriasis
Conditions
Scalp Psoriasis
Trial Timeline
Oct 22, 2018 → Mar 15, 2019
NCT ID
NCT03880357About Betamethasone Scalp Suspension 0.064%;0.0005% + Taclonex® + Placebo topical suspension
Betamethasone Scalp Suspension 0.064%;0.0005% + Taclonex® + Placebo topical suspension is a phase 1 stage product being developed by Sun Pharmaceutical for Scalp Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03880357. Target conditions include Scalp Psoriasis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03880357 | Phase 1 | Completed |
Competing Products
7 competing products in Scalp Psoriasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DSXS topical product | Sun Pharmaceutical | Phase 2 | 52 |
| PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment Extension | Sun Pharmaceutical | Phase 3 | 77 |
| DSXS + Placebo | Sun Pharmaceutical | Phase 3 | 77 |
| DSXS topical + Vehicle topical | Sun Pharmaceutical | Phase 3 | 77 |
| Calcipotriene/Betamethasone Dipropionate + Taclonex® + Placebo | Glenmark Pharmaceuticals | Phase 3 | 77 |
| Secukinumab 300 mg + Placebo | Novartis | Phase 3 | 77 |
| Roflumilast Foam 0.3% + Vehicle Foam | Arcutis Biotherapeutics | Phase 3 | 72 |
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85